Bachrach departs
This article was originally published in The Tan Sheet
Executive Summary
CHPA Senior VP, General Counsel and Secretary Eve Bachrach will retire from the association later this summer after 21 years of service, the group said in a same-day announcement. Since joining CHPA in 1985, Bachrach's accomplishments include involvement in Prescription Drug User Fee Act negotiations in 1992, which brought OTC NDAs parity review status with Rx drugs through the user fee process. She also helped develop national uniformity legislation for OTC drugs in 1997...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.